Disposal of Oral Fructose During Exercise

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Luc Tappy, MD, University of Lausanne
ClinicalTrials.gov Identifier:
NCT01128647
First received: May 21, 2010
Last updated: February 12, 2013
Last verified: February 2013
  Purpose

There is evidence that total carbohydrate oxidation during exercise is higher after ingestion of fructose:glucose mixture than after ingestion of equimolar amounts of glucose alone. This may possible contribute to improve performance, provided that the extra carbohydrate oxidation induced by fructose:glucose co-ingestion occurs in skeletal muscle. The present study aims at assessing the hypothesis that, during exercise, a substantial portion of oral fructose is converted into lactate prior to oxidation To identify the major pathways of fructose disposal, 7 healthy endurance trained male volunteers will be studied. For each participant the following measurement will be performed

  • a measurement of maximal oxygen consumption (VO2 max) on an ergometric bicycle
  • a 2 hour exercise protocol with oral administration of a glucose drink. 6,6-2H2 glucose (0.44 µmol/kg/min) and 13C3 lactate (2.25 µmol/kg/min) will be infused to calculate glucose and lactate kinetics. Indirect calorimetry will be performed to measure total carbohydrate oxidation and expired 13CO2 will be monitored to calculate whole body lactate oxidation
  • a 2 hour exercise protocol with oral administration of a glucose:fructose (72 + 48 g every hour) mixture. 6,6-2H2 glucose (0.44 µmol/kg/min) and 13C3 lactate (2.25 µmol/kg/min) will be infused to calculate glucose and lactate kinetics. Indirect calorimetry will be performed to measure total carbohydrate oxidation and expired 13CO2 will be monitored to calculate whole body lactate oxidation
  • a 2 hour exercise protocol with oral administration of a glucose:fructose (72 + 48 g every hour) mixture with fructose labelled with 13C6 fructose to evaluate exogenous fructose metabolic fate and oxidation. 6,6-2H2 glucose (0.44 µmol/kg/min) will be infused to calculate glucose kinetics. Fructose conversion into lactate and glucose will be evaluated by monitoring the systemic appearance of plasma 13C-labelled lactate and 13C-labelled glucose. Total exogenous fructose oxidation will be measured by monitoring 13CO2 production.

Based on these measurements, semi-quantitative estimates of total fructose oxidation, fructose conversion into glucose, fructose conversion into lactate, and oxidation of fructose-derived lactate will be obtained


Condition Intervention
Carbohydrate Metabolism at Exercise
Dietary Supplement: Fructose:glucose drink
Dietary Supplement: glucose drink

Study Type: Observational
Official Title: Disposal of Oral Fructose During Exercise

Resource links provided by NLM:


Further study details as provided by University of Lausanne:

Primary Outcome Measures:
  • Fructose conversion into lactate [ Time Frame: during a 2 hour-exercise at 60% VO2 max ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Total exogenous fructose oxidation [ Time Frame: during a 2 hour-exercise at 60% VO2 max ] [ Designated as safety issue: No ]
  • Fructose conversion into glucose [ Time Frame: during a 2 hour-exercise at 60% VO2 max ] [ Designated as safety issue: No ]
  • Oxidation of lactate derived from fructose [ Time Frame: during a 2 hour-exercise at 60% VO2 max ] [ Designated as safety issue: No ]

Enrollment: 7
Study Start Date: April 2009
Study Completion Date: March 2010
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Healthy, endurance trained male volunteers

Criteria

Inclusion Criteria:

  • age between 18 and 35 years
  • males
  • good physical health
  • weekly cycling training sessions (> 3 sessions/week)

Exclusion Criteria:

  • diabetes or glucose intolerance
  • past history of heart disease
  • alcohol intake > 30 g/day
  • smokers
  • drug consumption
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01128647

Locations
Switzerland
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland, CH-1011
Sponsors and Collaborators
University of Lausanne
  More Information

No publications provided by University of Lausanne

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Luc Tappy, MD, Professor of Physiology, University of Lausanne
ClinicalTrials.gov Identifier: NCT01128647     History of Changes
Other Study ID Numbers: Protocole 59/09
Study First Received: May 21, 2010
Last Updated: February 12, 2013
Health Authority: Switzerland: Ethikkommission

ClinicalTrials.gov processed this record on October 21, 2014